Article Per Year (5 Year)
p-Index From 2020 - 2025
0.61
P-Index
This Author published in this journals
All Journal Medical Journal of Indonesia eJournal Kedokteran Indonesia Jurnal Penyakit Dalam Indonesia
Maria, Suzy
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Mutation and Variant of Coronavirus Disease 2019 (COVID-19): Review of Current Literatures Susilo, Adityo; Jasirwan, Chyntia Olivia Maurine; Wafa, Syahidatul; Maria, Suzy; Rajabto, Wulyo; Muradi, Akhmadu; Fachriza, Ihza; Putri, Myranda Zahrah; Gabriella, Stacy
Jurnal Penyakit Dalam Indonesia Vol. 9, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Since March 2020, the Coronavirus Disease 2019 (COVID-19) pandemic has engulfed the world, including Indonesia, for nearly two years. SARS-CoV-2 has undergone several mutations during its evolution as a pathogen, resulting in various variants of global concern. Variants of this virus are suspected to impede the outbreak resolution and possibly causing the outbreak to spiral out of control. There is still considerable debate and research underway regarding the new SARS-CoV-2 variants. Rapid transmission mechanisms and widespread vaccination coverage have accelerated the virus’s mutation rate and resulted in numerous new variants. To date, this has resulted in the discovery of a new variant Omicron (B.1.1.529) in November 2021 in South Africa, which has since spread to 103 countries. Omicron is designated a Variant of Concern (VoC) due to its more powerful transmission than the previous variant. Although some information indicates that the symptoms associated with this variant are typically mild, the rapid transmission of Omicron can increase the next wave of COVID-19 cases. Additional research is required to determine transmissibility, pathogenesis, diagnosis, and proper management. As a result, we conducted an adjunct to studies on various COVID-19 mutations and variants until January 2022.
Safety and immunogenicity of the CoV2-Bio in a healthy population aged 18 years and older in Indonesia Maria, Suzy; Olfriani, Ciho; Koesnoe, Sukamto; Sekartini, Rini; Soedjatmiko; Medise, Bernie Endyarni; Yuniar, Irene; Indawati, Wahyuni; Wirahmadi, Angga; Sari, Rini Mulia; Adi, Nuri Purwito; Retnaningdyah, Windri
Medical Journal of Indonesia Vol. 34 No. 1 (2025): March
Publisher : Faculty of Medicine Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.13181/mji.oa.247476

Abstract

BACKGROUND According to the WHO Target Product Profiles for COVID-19 Vaccines, vaccine development should be indicated for active immunization in all populations, in conjunction with other control measures to curtail the pandemic. Several RBD-based COVID-19 vaccines are being evaluated and have shown advantages. CoV2-Bio was developed based on the wild-type SARS-CoV-2 RBD amino acid sequence, representing residues of the spike protein of the Wuhan-Hu-1 isolate. This study aimed to evaluate the safety and immunogenicity of CoV2-Bio when compared to CoronaVac. METHODS This was an observer-blinded, randomized controlled prospective study of safety and immunogenicity of the CoV2-Bio in healthy adult population. A total of 54 healthy participants were randomized to receive either 3 doses of CoV2-Bio or 2 doses of CoronaVac, and 1 dose of placebo, administered 28 days apart. Participants were followed up for safety and immunogenicity. IgG antibody titers (ELISA) and neutralization assay against Wuhan and Delta strains were evaluated at baseline, Days 28, 56, and 84. We assessed seropositive rate, seroconversion, and GMT as parameters. RESULTS Both vaccines were well tolerated and induced good antibody response. The incidence rate and intensity of local and systemic adverse events did not differ between vaccine and control groups. The vaccine group showed a larger proportion of seroconversion (4-fold increase antibody) (87.5% versus 46.2%, p = 0.001) and higher GMT (305.9 AU/ml versus 102.4 AU/ml, p<0.001) when compared to control group. CONCLUSIONS 3 doses of the CoV2-Bio are safe and immunogenic in healthy adult population. 3 doses of the CoV2-Bio COVID-19 vaccine produce a better immunogenicity profile compared to CoronaVac.
Effect of Bisphosphonate in Preventing Hungry Bone Syndrome in Patients with Primary Hyperparathyroidism Undergoing Parathyroidectomy Baihaqi, Fahri Ahmad; Magdalena, Bellinda; Maria, Suzy
eJournal Kedokteran Indonesia Vol. 13 No. 1 (2025): Vol 13, No. 1 - April 2025
Publisher : Faculty of Medicine Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.23886/ejki.13.801.80

Abstract

Primary hyperparathyroidism is a common endocrine disorder that often requires parathyroid-dectomyas a curative measure. However, post-operatively, patients are susceptible to severe and prolongedhypocalcemia, known as post-parathyroidectomy hypocalcemia syndrome (HBS), which can prolong the lengthof stay and increase the cost of care. Preoperative use of bisphosphonates has been proposed as a potentialtherapy to reduce the incidence of HBS. This EBCR aims to determine the effectiveness of preoperativebisphosphonate administration in reducing the risk of HBS in patients with primary hyperparathyroidismundergoing parathyroidectomy. A systematic literature review conducted through three electronic databasesand critical analysis using FAITH tools from the Central of Evidence-based Medicine, University of Oxford,showed that pre-operative administration of bisphosphonates significantly reduces the occurrence of HBSwith an overall NNT (Number Needed to Treat) of three. However, further research is needed to validatebisphosphonates’ effectiveness and safety in this context. Overall, these EBCR suggest that bisphosphonatescan be considered as part of a preventive strategy for HBS in patients with primary hyperparathyroidismundergoing parathyroidectomy.
Co-Authors Adityo Susilo, Adityo Baihaqi, Fahri Ahmad Bernie Endyarni Medise Chyntia Olivia Maurine Jasirwan, Chyntia Olivia Maurine Fachriza, Ihza Gabriella, Stacy Irene Yuniar, Irene Magdalena, Bellinda Muradi, Akhmadu Nuri Purwito Adi Olfriani, Ciho Putri, Myranda Zahrah Retnaningdyah, Windri Rini Mulia Sari Rini Sekartini Soedjatmiko Sukamto Koesnoe Syahidatul Wafa, Syahidatul Wahyuni Indawati, Wahyuni Wirahmadi, Angga Wulyo Rajabto